Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 14/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11917554 | 1.00 | SIRT1 (0.40) | SIRT1KIF11TP53MAPTSMN1; SMN2 | |
| SCHEMBL11912937 | 0.88 | TP53 (0.47) | KIF11TP53MAPTSMN1; SMN2ABCG2 | |
| SCHEMBL9962085 | 0.88 | TP53 (0.47) | KIF11TP53MAPTSMN1; SMN2ABCG2 | |
| SCHEMBL16299521 | 0.83 | KIF11 (0.48) | SIRT1KIF11TP53MAPTSMN1; SMN2 | |
| SCHEMBL12980183 | 0.82 | TP53 (0.45) | KIF11TP53MAPTSMN1; SMN2ABCG2 | |
| SCHEMBL11912609 | 0.80 | TP53 (0.48) | KIF11TP53MAPTSMN1; SMN2ABCG2 | |
| SCHEMBL22238497 | 0.80 | KIF11 (0.38) | SIRT1KIF11TP53MAPTSMN1; SMN2 | |
| SCHEMBL16358487 | 0.79 | SIRT1 (0.42) | SIRT1KIF11TP53MAPTSMN1; SMN2 | |
| SCHEMBL11912610 | 0.79 | TP53 (0.47) | SIRT1KIF11TP53MAPTSMN1; SMN2 | |
| SCHEMBL16359684 | 0.78 | KIF11 (0.42) | SIRT1KIF11TP53MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202763-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202801-A1 | METHODS FOR TREATING BREAST CANCER | PTC THERAPEUTICS, INC. | 2012-08-09 | — | — | US | disclosed |
| US-20120178707-A1 | METHODS FOR TREATING PROSTRATE CONDITIONS | PTC THERAPEUTICS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-20120157401-A1 | METHODS FOR TREATING NEUROFIBROMATOSIS | PTC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202763-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | SIRT1 2518/4885KIF11 2569/4885TP53 16/4885 |
| US-20120157401-A1 | METHODS FOR TREATING NEUROFIBROMATOSIS | VHL, NGF, VEGFA | SIRT1 1929/4885KIF11 1626/4885TP53 99/4885 |
| US-20120202801-A1 | METHODS FOR TREATING BREAST CANCER | VEGFA, FLT4, FLT1 | SIRT1 687/4885KIF11 1215/4885TP53 34/4885 |
| US-20120178707-A1 | METHODS FOR TREATING PROSTRATE CONDITIONS | ACP3, BPHL, PTGFR | SIRT1 552/4885KIF11 1310/4885TP53 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.